Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient

Annals of Transplantation

Volumn 16, Issue 4, 2011, Pages 107-110

  FijaŁkowska Morawska, Jolanta Barbara ^a   Jagodzińska, Marta ^a   Nowicki, MichaŁ ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Everolimus; Kidney transplantation; Pulmonary embolism; Tuberculosis reactivation

Indexed keywords

ACENOCOUMAROL; CREATININE; ENOXAPARIN; EVEROLIMUS; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; TACROLIMUS;

AGED; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BASAL CELL CARCINOMA; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COUGHING; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSPNEA; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; LUNG FIBROSIS; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; RIGOR; THORAX PAIN; THORAX RADIOGRAPHY;

EID: 84855473123     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882226     Document Type: Article

References (17)

1. Briggs JD: Causes of death after renal transplantation. Nephrol Dial Transplant, 2001; 16: 1545-49
2. Neumayer HH: Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation, 2005; 79(Suppl.9): S72-75
3. Fernandez A, Marcèn R, Pascual J et al: Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc, 2006; 38: 2453-55
4. Crowson AN: Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol, 2006; 19: S127-47
5. Eisen HJ, Tuzcu EM, Dorent R et al: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med, 2003; 349: 847-58
6. Lingaraju R, Blumenthal NP, Mendez J et al: Venous thromboembolic disease after lung transplantation: special focus on sirolimus. Open Transplant J, 2010; 4: 1-4
7. Ahya VN, McShane PJ, Baz MA et al: Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant, 2011; 30: 175-81
8. Pohanka E: Conversion to everolimus in maintenance patients - current clinical strategies. Nephrol Dial Transplant, 2006; 21(Suppl.3): iii24-29
9. Kovarik JM, Hartmann S, Figueiredo J et al: Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother, 2002; 36: 981-85
10. Kuypers DR: Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging, 2009; 26: 715-37
11. Gallagher MP, Kelly PJ, Jardine M et al: Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol, 2010; 21: 852-58
12. Snell GI, Valentine VG, Vitulo P et al: Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant, 2006; 6: 169-77
13. Stone GW, Midei M, Newman W et al: Randomized comparison of everolimus-eluting and paclitaxel- eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation, 2009; 119: 680-86
14. Langer RM, Kahan BD: Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation, 2003; 76: 318-23
15. Zangari M, Fink LM, Elice F et al: Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol, 2009; 27: 4865-73
16. Muldowney JA III, Stringham JR, Levy SE et al: Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Artherioscler Thromb Vasc Biol, 2007; 27: 400-6
17. Currie AC, Knight SR, Morris PJ: Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation, 2010; 90: 695-704